ResearcherBoston UniversityNo recent work listed

Ariana M. Chirban

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5012154163. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2023: 1 paper

Papers 1

R1 pancreatic cancer patients benefit from chemoradiation when initiation of adjuvant therapy is delayed. Co-author DOI 10.1016/j.suronc.2023.101961 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Sebastián Mellado · 1 shared paper, 2023 · strength 0.18
- Paper R1 pancreatic cancer patients benefit from chemoradiation when initiation of adjuvant therapy is delayed. DOI 10.1016/j.suronc.2023.101961 ↗
Oscar Salirrosas · 1 shared paper, 2023 · strength 0.18
- Paper R1 pancreatic cancer patients benefit from chemoradiation when initiation of adjuvant therapy is delayed. DOI 10.1016/j.suronc.2023.101961 ↗
Claudius H. Conrad · 1 shared paper, 2023 · strength 0.18
- Paper R1 pancreatic cancer patients benefit from chemoradiation when initiation of adjuvant therapy is delayed. DOI 10.1016/j.suronc.2023.101961 ↗
Onur Cagri Kutlu · 1 shared paper, 2023 · strength 0.18
- Paper R1 pancreatic cancer patients benefit from chemoradiation when initiation of adjuvant therapy is delayed. DOI 10.1016/j.suronc.2023.101961 ↗
Eduardo A. Vega · 1 shared paper, 2023 · strength 0.18
- Paper R1 pancreatic cancer patients benefit from chemoradiation when initiation of adjuvant therapy is delayed. DOI 10.1016/j.suronc.2023.101961 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.